REG - Diaceutics PLC - Issue of Share Options/PDMR Shareholdings
19/05/2023 10:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230519:nRSS0347Aa&default-theme=true
RNS Number : 0347A Diaceutics PLC 19 May 2023
19 May 2023
Diaceutics PLC
("Diaceutics" or "the Company")
Issue of Share Options/PDMR Shareholdings
Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the
pharmaceutical industry, announces the issue of 1,276,707 share options over
ordinary shares of £0.002 each in the Company ("Share Options") to certain
directors, members of the Company's senior management team and other key
staff, pursuant to the Company's Employee Share Option Plan ("ESOP"). These
awards are made in accordance with the Company's long term incentive plan as
detailed in the Company's Annual Report.
Share Options were granted as follows:
Name Number of Share Options granted Total no. of ordinary shares under option post grant % of existing issued share capital Effective Grant date
Peter Keeling, CEO 102,468 435,313 0.52% 18 May 2023
Nick Roberts, CFO 67,034 158,872 0.19% 18 May 2023
Ryan Keeling, CIO 93,407 409,851 0.49% 18 May 2023
Julie Browne, COO and PDMR 67,109 169,047 0.20% 18 May 2023
Jordan Clark, CCO and PDMR 65,245 115,740 0.14% 18 May 2023
Susanne Munksted, CPO and PDMR 68,834 249,199 0.30% 18 May 2023
Other employees (43 persons) 812,610 1,675,537 1.98% 18 May 2023
The Share Options vest on a sliding scale up to 100%, after three years from
the date of grant (the "Performance Period"), subject to the satisfaction of
certain performance criteria. The performance criteria are based upon the
growth in the proportion of subscription revenue and Total Shareholder Return
("TSR") during the Performance Period. The growth in TSR will be measured
against a base share price of 103.97p, being the average mid-market closing
share price in the three days prior to 18 May 2023. The exercise price of the
Share Options is £0.002 per share which equates to the nominal value of the
ordinary shares.
Following this grant, the total number of share options outstanding in the
Company is 3,826,487 representing approximately 4.52% of its current issued
share capital of 84,461,386.
Enquiries:
Diaceutics PLC
Peter Keeling, Chief Executive Officer Via Alma PR
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600
Ben Maddison, Nick Harland, Nick Adams
Alma PR Tel: +44(0)20 3405 0205
Caroline Forde, Kieran Breheny, Matthew Young diaceutics@almapr.co.uk
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharmaceutical and life
science companies with solutions and technology for the commercialisation of
their precision medicines, enabled by the proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform for precision
medicine, utilising a global network of affiliate laboratories to deliver
multiple pipelines of real‐world healthcare data insights, advisory services
and innovative platform enabled solutions.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Peter Keeling
2 Reason for notification
a. Position/Status Chief Executive Officer, Director
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 102,468
e. Date of the transaction 18 May 2023
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Nick Roberts
2 Reason for notification
a. Position/Status Chief Finance Officer, Director
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 67,034
e. Date of the transaction 18 May 2023
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Ryan Keeling
2 Reason for notification
a. Position/Status Chief Innovation Officer, Director
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 93,407
e. Date of the transaction 18 May 2023
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Julie Browne
2 Reason for notification
a. Position/Status Chief Operations Officer and PDMR
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 67,109
e. Date of the transaction 18 May 2023
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Jordan Clark
2 Reason for notification
a. Position/Status Chief Commercial Officer and PDMR
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 65,245
e. Date of the transaction 18 May 2023
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Susanne Munksted
2 Reason for notification
a. Position/Status Chief Precision Medicine Officer and PDMR
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 68,834
e. Date of the transaction 18 May 2023
f. Place of the transaction Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHKKLBFXELFBBZRecent news on Diaceutics
See all newsREG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan and TVR
AnnouncementREG - Diaceutics PLC - Notice of Results
AnnouncementREG - Diaceutics PLC - Block Listing Return
AnnouncementREG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan and TVR
AnnouncementREG - Diaceutics PLC - PMx Promotional Partner Contract Enhancement
Announcement